capecitabine (metronomic)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for capecitabine (metronomic), covering 2022-11-04 to 2022-11-04. Get the full timeline:
Most recent: Clinical Trial Update: Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. [Phase 2]